Secondary Arterial Hypertension in Patients with a Neuroendocrine Tumor of the Adrenal Glands
The article aims to stress the importance of revealing the causes of arterial hypertension (AH) and providing differential diagnostics. Being a globally spread issue that is discussed by healthcare ptofessionals worldwide, hypertension may be described as a medical and social problem. Most clinical examples are accompanied with the presence of an essential form of hypertension, though 5–25 % of cases are attributed specifically to the secondary (symptomatic) form of hypertension (SAH). This article discusses such a case in a young patient with pheochromocytoma. This clinical instance is an illustration of SAH development, which requires a competent study of the root cause, given the complexity of diagnosis at the initial stages of the disease, as well as the correct choice of patient management tactics.
Khorolets E.V., Shaposhnikova S.S., Otrutsky S.S., Parshikov E.G. 2025. Secondary Arterial Hypertension in Patients with a Neuroendocrine Tumor of the Adrenal Glands. Challenges in Modern Medicine, 48(4): 468–483 (in Russian). DOI: 10.52575/2687-0940-2025-48-4-468-483. EDN: MAAAQT
While nobody left any comments to this publication.
You can be first.
Aksenova A.V., Sivakova O.A., Blynova N.V., Danilov N.M., Elfimova E.M., Kislyak O.A., Litvin A.Yu., Oshchepkova E.V., Fomin V.V., Chihladze N.M., Shchelkova G.V., Chazova I.E. 2021. The Consensus of Experts of the Russian Medical Society on Arterial Hypertension on the Diagnosis and Treatment of Resistant Arterial Hypertension. Therapeutic Archive. 93(9): 1018–1029. doi: 10.26442/00403660.2021.09.201007
Artamonova E.V., Beltsevich D.G., Bokhyan V.Yu., Geliashvili T.M., Gorbunova V.A., Delektorskaya V.V., Dolgushin M.B., Egorov A.V., Yemelyanova G.S., Zhukova L.G., Zhulikov Ya.A., Kasprzyk S.M., Krylov A.S., Kuzminov A.E., Lyubimova N.V., Markovich A.A., Melnichenko G.A., Orel N.F., Orlov S.V., Orlova K.V., Orlova R.V., Pronin A.I., Romanov I.S., Trifanov V.S., Khomyakov V.M., Petrov L.O., Pirogov S.S., Fedenko A.A., Bolotina L.V., Falaleeva N.A., Filonenko E.V., 2025. Clinical Guidelines "Neuroendocrine Tumors", Russian Association of Endocrinologists, Association of Oncologists of Russia, All-Russian Public Organization. Russian Society of Clinical Oncology. https://gastroscan.ru/literature/authors/15346
Vaichulis I.A., Shaposhnik I.I. 2019. The Main Provisions of the International Recommendations for the Detection of Endocrine Hypertension. Cardiology. 59(10): 88–96. doi: 10.18087/cardio.2019.10.2669
Kobalava Zh.D., Konradi A.O., Nedogoda S.V., Shlyakhto E.V., Arutyunov G.P., Baranova E.I., Barbarash O.L., Boytsov S.A., Vavilova T.V., Villevalde S.V., Galyavich A.S., Glezer M.G., Grineva E.N., Grinstein Yu.I., Drapkina O.M., Zhernakova Yu.V., Zvartau N.E., Irtyuga O.B., Kislyak O.A., Koziolova N.A., Kosmacheva E.D., Kotovskaya Yu.V., Bobkova N.V., Libis R.A., Lopatin Yu.M., Nebiridze D.V., Nedoshivin A.O., Nikulina S.Yu., Ostroumova O.D., Oschepkova E.V., Ratova L.G., Salasyuk A.S., Skibitsky V.V., Tkacheva O.N., Troitskaya E.A., Chazova I.E., Chesnikova A.I., Chumakova G.A., Shalnova S.A., Shestakova M.V., Yakushin S.S., Yanishevsky S.N. 2024. Clinical Guidelines. Arterial Hypertension in Adults. Russian Journal of Cardiology. 29(9): 6117. doi: 10.15829/1560-4071-2024-6117. EDN: GUEWLU
Melnichenko G.A., Dedov I.I., Belaya Zh.E., Rozhinskaya L.Ya., Vagapova G.R., Volkova N.I., Grigor’ev A.Yu., Grineva E.N., Marova E.I., Mkrtumayn A.M., Trunin Yu.Yu., Cherebillo V.Yu. 2015. Cushing’s Disease: The Clinical Features, Diagnostics, Differential Diagnostics, and Methods of Treatment. Problems of Endocrinology. 61(2): 55–77. doi: 10.14341/probl201561255-77
Muradian A.G., Kostin A.A., Vorobyov N.V., Tolkachev A.O. 2020. Metastatic Tumors of the Adrenal Gland. Epidemiology, Etiology, and Diagnosis. Oncology. P.A. Herzen Magazine. 9(3): 53–60. doi: 10.17116/onkolog2020903153
Chazova I.E., Chikhladze N.M., Blinova N.V., Belaya Zh.E., Danilov N.M., Elfimova E.M., Litvin A.Yu., Rozhinskaya L.Ya., Sviridenko N.Yu., Shvetsov M.Yu., Azizov V.A., Grigorenko E.A., Mitkovskaya N.P., Mustafaev I.I., Polupanov A.G., Sarybaev A.Sh., Khamidullayeva G.A. 2023. Eurasian Clinical Guidelines for the Diagnosis and Treatment of Secondary (Symptomatic) Forms of Arterial Hypertension (2022). Eurasian Journal of Cardiology. (1): 6–65. doi: 10.38109/2225-1685-2023-1-6-65
Chikhladze N.M. 2020. Primary Hyperaldosteronism as a Possible Cause of the Resistant Course of Arterial Hypertension. Systemic Hypertension. 17(4): 20–23. doi: 10.26442/ 2075082X.2020.4.200338
Chikhladze N.M. Primary Hyperaldosteronism: Indications for Screening. 2022. Therapeutic Archive. 94(1): 107–113. doi: 10.26442/00403660.202 2.01.201324
Yukina M.Yu., Troshina E.A., Beltsevich D.G. 2015. Hereditary Syndromes Associated with Pheochromocytoma. Part 1. Therapeutic Archive. 87(9): 102–105. doi: 10.17116/ terarkh2015879102-105
Antonio K., Valdez M.M.N., Mercado-Asis L., Taïeb D., Pacak K. 2020. Pheochromocytoma/ paraganglioma: Recent Updates in Genetics, Biochemistry, Immunohistochemistry, Metabolomics, Imaging and Therapeutic Options. Gland Surg. 9(1): 105–123. doi: 10.21037/gs.2019.10.25
Aygun N., Uludag M. 2020. Pheochromocytoma and Paraganglioma: From Epidemiology to Clinical Findings. Sisli Etfal Hastan Tip Bul. 54: 159–68. doi: 10.14744/SEMB.2020.18794
Boot C.S. 2023. A Laboratory Medicine Perspective on the Investigation of Phaeochromocytoma and Paraganglioma. Diagnostics (Basel). 13: 2940. doi: 10.3390/diagnostics13182940
Dogrul A.B., Cennet O., Dincer A.H. 2022. Minimally Invasive Techniques in Benign and Malignant Adrenal Tumors. World J Clin cases. 10(35): 12812–12821. doi: 10.12998/wjcc.v10.i35.12812
Ebbehoj A., Stochholm K., Jacobsen S.F. Trolle Ch., Jepsen P., Robaczyk M.G., Rasmussen A.K., Feldt-Rasmussen U., Thomsen R.W., Søndergaard E., Poulsen P.L. 2021. Incidence and Clinical Presentation of Pheochromocytoma and Sympathetic Paraganglioma: A Population-based Study. J. Clin. Endocrinol. Metab. 106(5): e2251-e2261. doi: 10.1210/clinem/dgaa965
Garcia-Carbonero R., Matute Teresa F., Mercader-Cidoncha E., Mitjavila-Casanovas M., Robledo M., Tena I., Alvarez-Escola C., Arístegui M., Bella-Cueto M.R., Ferrer-Albiach C., Hanzu F.A. 2021. Multidisciplinary Practice Guidelines for the Diagnosis, Genetic Counseling and Treatment of Pheochromocytomas and Paragangliomas. Clin Transl Oncol. 23: 1995–2019. doi: 10.1007/s12094-021-02622-9
Lima J.V., Kater C.E. 2023. The Pheochromocytoma/Paraganglioma Syndrome: An Overview on Mechanisms, Diagnosis and Management. Int Braz J Urol. 49: 307–19. doi: 10.1590/S1677-5538.IBJU.2023.0038
Marcus C., Subramaniam R.M. 2023. Paragangliomas and Pheochromocytomas: Positron Emission Tomography/Computed Tomography Diagnosis and Therapy. PET Clin. 18: 233–42. doi: 10.1016/j.cpet.2022.11.006
Mete O., Asa S.L., Gill A.J., Kimura N., de Krijger R.R., Tischler A. 2022. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas. Endocr Pathol. 33: 90–114. doi: 10.1007/s12022-022-09704-6
Mills K.T., Stefanescu A., He J. 2020. The Global Epidemiology of Hypertension. Nat Rev Nephrol. 16(4): 223–37. doi: 10.1038/s41581-019-0244-2
Nölting S., Bechmann N., Taieb D., Beuschlein F., Fassnacht M., Kroiss M., Graeme Eisenhofer G., Grossman A., Pacak K. 2022. Personalized Management of Pheochromocytoma and Paraganglioma. Endocr Rev. 43: 199–239. doi: 10.1210/endrev/bnab019
Passman J.E., Wachtel H. 2024. Management of Pheochromocytomas and Paragangliomas. Surg Clin North Am. 104:863–81. doi: 10.1016/j.suc.2024.02.014
Sarathy H., Salman L.A., Lee C., Cohen J.B. 2022. Evaluation and Management of Secondary Hypertension. Med Clin North Am. 106(2): 269–83. doi: 10.1016/j.mcna.2021.11.004
Schmiemann G., Gebhardt K., Hummers-Pradier E., Egidi G. 2012. Prevalence of Hyperaldosteronism in Primary Care Patients with Resistant Hypertension. J Am Board Fam Med. Jan-Feb; 25(1): 98–103. doi: 10.3122/jabfm.2012.01.110099
Sharma S., Fishbein L. 2023. Diagnosis and Management of Pheochromocytomas and Paragangliomas: A Guide for the Clinician. Endocr Pract. 29: 999–1006. doi: 10.1016/j.eprac.2023.07.027
Informed consent. The patient's informed consent was obtained for the publication of data from his examination, survey, and clinical observation. All patient data was de-identified.